XML 23 R42.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Alliances and Collaborations Statement [Line Items]      
Net sales $ 3,831 $ 5,251  
Amortization expense - upfront, milestone and other licensing payments 216 101  
Other (income)/expense (19) (184)  
Other intangible assets - upfront, milestone and other licensing payments 8,570   8,778
Erbitux [Member]
     
Alliances and Collaborations Statement [Line Items]      
Net sales 162 179  
Lilly [Member] | Upfront, milestone and other licensing payments [Member]
     
Alliances and Collaborations Statement [Line Items]      
Amortization expense - upfront, milestone and other licensing payments 9 10  
Other intangible assets - upfront, milestone and other licensing payments 202   211
Lilly [Member] | Erbitux [Member]
     
Alliances and Collaborations Statement [Line Items]      
Net sales 162 179  
Lilly [Member] | Erbitux [Member] | North America [Member]
     
Alliances and Collaborations Statement [Line Items]      
Distribution fee, percentage of net sales 39.00%    
Distribution fees and royalty expense 67 74  
Lilly [Member] | necitumumab [Member]
     
Alliances and Collaborations Statement [Line Items]      
Research and development reimbursements to/(from) collaboration partner   1  
Lilly [Member] | Erbitux And Necitumumab [Member] | Upfront, milestone and other licensing payments [Member]
     
Alliances and Collaborations Statement [Line Items]      
Total upfront, milestone and other licensing payments 500    
Lilly [Member] | Byetta And Bydureon [Member] | Non United States [Member]
     
Alliances and Collaborations Statement [Line Items]      
Maximum amount payable to alliance partner for losses 60    
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member]
     
Alliances and Collaborations Statement [Line Items]      
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner. 50.00%    
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member] | Commercialization fee [Member]
     
Alliances and Collaborations Statement [Line Items]      
Other (income)/expense $ (4) $ (6)